8 enrolling by invitation. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Enrolling by invitation 8 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Standard of Care - Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | Celldex Therapeutics | 1370 | 2025-11-25 | 2026-10-07 |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. 10mg QY201 Placebo tablet, 20mg QY201 Placebo tablet, 10mg QY201 tablet - Atopic Dermatitis (AD) | Phase 3 | Enrolling by invitation | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 460 | 2025-03-12 | 2025-09-18 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) Dupilumab, Placebo - Wheezing, Asthma | Phase 3 | Enrolling by invitation | Sanofi | 90 | 2024-01-03 | 2026-08-13 |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis, Eczema | Phase 3 | Enrolling by invitation | Eli Lilly and Company | 338 | 2023-03-09 | 2026-10-26 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies berotralstat - Hereditary Angioedema, HAE | Phase 3 | Enrolling by invitation | BioCryst Pharmaceuticals | 139 | 2021-07-23 | 2025-12-23 |
Angioedemas, Hereditary (4) · Dermatitis, Atopic (2) · Angioedema (1) · Asthma (1) · Chronic Urticaria (1) · Eczema (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1) · Respiratory Sounds (1)
Hypersensitivity, Immediate (8) · Immune System Diseases (8) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Skin Diseases, Vascular (5) · Urticaria (5) · Cardiovascular Diseases (4) · Hereditary Complement Deficiency Diseases (4) · Immunologic Deficiency Syndromes (4) · Primary Immunodeficiency Diseases (4) · Vascular Diseases (4) · Angioedema (3)
Standard of Care (1) · berotralstat (1) · dupilumab (1) · lebrikizumab (1)
Pharvaris Netherlands B.V. (2) · Astria Therapeutics, Inc. (1) · BioCryst Pharmaceuticals (1) · Celldex Therapeutics (1) · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (1) · Eli Lilly and Company (1) · Sanofi (1)
Canada (7) · France (7) · Germany (7) · Poland (7) · Spain (7) · Czechia (6) · United Kingdom (6) · United States (6) · Argentina (5) · Brazil (5) · Italy (5) · Japan (5) · South Africa (5) · Australia (4) · Bulgaria (4)
Vesna Grivcheva-Panoska, MD, PhD (1)
2023 (2)